Producer
D.O.R.C. (Dutch Ophthalmic Research Center)
Vitreoretinal surgery systems (EVA NEXUS), instruments and surgical liquids incl. silicone oil tamponades. Founded 1983; acquired 100% by Carl Zeiss Meditec from Eurazeo for ~€985M, completed April 2024.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input D.O.R.C. (Dutch Ophthalmic Research Center) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something D.O.R.C. (Dutch Ophthalmic Research Center) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Vitreoretinal Surgical Systems (EVA NEXUS)
45%Surgical Liquids & Tamponades
30%Vitreoretinal Instruments
25%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
DORC is now a subsidiary of Carl Zeiss Meditec, which is itself a division of Carl Zeiss AG — the German optics company that also owns Carl Zeiss SMT (Semiconductor Manufacturing Technology). Carl Zeiss SMT is the sole manufacturer of the extreme ultraviolet (EUV) optical lens systems inside ASML's EUV lithography scanners — the machines that print the world's most advanced semiconductor chips (5nm, 3nm, 2nm nodes). Zeiss SMT's EUV optics are the most precise manufactured objects on earth (sub-nanometer surface roughness, active vibration compensation). The same Carl Zeiss corporate conglomerate that makes the optics enabling TSMC, Samsung, and Intel to fabricate advanced chips also makes the vitreoretinal surgery machines that surgeons use to repair detached retinas. An export restriction on Carl Zeiss products, or a geopolitical disruption affecting Zeiss's Oberkochen, Germany manufacturing, would simultaneously impact global semiconductor lithography supply and ophthalmic surgery equipment worldwide.
Carl Zeiss AG ↗Concentration2024
The vitreoretinal surgery capital equipment market is consolidating into three platforms: Alcon CONSTELLATION, DORC EVA NEXUS (now Zeiss-owned), and minor players. Alcon has approximately 55-60% share, DORC-Zeiss has 30-35%, and others (BVI Medical, others) hold the remainder. Vitreoretinal surgical system selection is a hospital-level capital decision with 7-12 year replacement cycles, creating strong switching costs and consumables lock-in. Once a hospital purchases an EVA NEXUS or CONSTELLATION system, they are effectively committed to purchasing that vendor's PFCL, silicone oil, vital dyes, and surgical instruments for the lifetime of the machine. The Zeiss-DORC acquisition is partly a play to lock hospitals into the Zeiss consumables ecosystem the same way that Alcon's surgical systems lock hospitals into Alcon's IOL and silicone oil ecosystem.
DORC International (Carl Zeiss Meditec) ↗Origin2024
DORC (Dutch Ophthalmic Research Center) was founded in 1983 in Zuidland, Netherlands, developing the EVA vitreoretinal surgical system to compete with Alcon's CONSTELLATION platform. DORC remained an independent Dutch company until private equity firm Eurazeo acquired it. In April 2024, Carl Zeiss Meditec (the ophthalmic division of Carl Zeiss AG) completed a €985M acquisition of DORC — one of the largest ophthalmic industry M&A deals of the decade. The acquisition brings DORC's vitreoretinal platform into the Carl Zeiss group alongside their OCT imaging (CIRRUS, RESCAN), laser platforms, and microsurgery microscopes. Zeiss-DORC now offers surgeons an end-to-end vitreoretinal workflow from pre-op imaging (OCT) through intraoperative visualization (OPMI LUMERA microscope + EVA NEXUS) through consumables (silicone oil, PFCL, vital dyes) — a vertically integrated platform strategy similar to how Alcon bundles CONSTELLATION + IOL + Systane.
Carl Zeiss Meditec AG ↗